Last reviewed · How we verify
Iminoral
Iminoral is a Small molecule drug developed by Imam Khomeini Hospital. It is currently FDA-approved.
Cyclosporine Inhalation Solution is being studied as a treatment for conditions such as Constrictive Bronchiolitis, Bronchiolitis Obliterans, and Graft vs Host Disease. It is being compared to other interventions like Methotrexate and Cyclophosphamide in clinical trials for these conditions.
At a glance
| Generic name | Iminoral |
|---|---|
| Sponsor | Imam Khomeini Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita (PHASE2)
- Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases (PHASE1, PHASE2)
- Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy (PHASE2)
- Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-Associated Hemophagocytic Lymphohistiocytosis (NA)
- A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy (PHASE3)
- A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256) (PHASE2)
- Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia (PHASE2)
- Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Iminoral CI brief — competitive landscape report
- Iminoral updates RSS · CI watch RSS
- Imam Khomeini Hospital portfolio CI
Frequently asked questions about Iminoral
What is Iminoral?
Who makes Iminoral?
What development phase is Iminoral in?
Related
- Manufacturer: Imam Khomeini Hospital — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing